Activation Immunotherapy Resolves Symptoms of Chronic Disease

A novel immunotherapy, which has shown efficacy in many chronic diseases, has been developed following identification of a mechanism that triggers chronic inflammation. Intracellular bacteria appear to cause immune system dysfunction by down-regulating the vitamin D receptor (VDR). The result is elevated 1,25-dihydroxyvitamin-D (calcitriol), non-resolving inflammation, persistent infection, and eventual multi-morbidity.

The angiotensin receptor blocker olmesartan (Benicar®), when administered at higher than anti-hypertensive doses, appears to be an agonistic VDR ligand which up-regulates the bacterially-inhibited VDR. Clinically, this is evidenced by a significant decrease in elevated calcitriol. To help eradicate the intracellular pathogens, very low-dose, oral antibiotics are administered on a pulsed schedule. Elimination of bacteria is evidenced by periodic Jarisch-Herxheimer reactions (immunopathology) and a gradual reduction of inflammatory symptoms. The medication regimen is adjusted frequently to maintain tolerable immunopathology symptoms during the recovery process.

There is an increasing number of chronically ill patients with multi-morbidity and a lack of efficacious therapies. Patients with a wide variety of autoimmune or inflammatory diseases who were treated with this new immunotherapy demonstrated significant symptom resolution. Many had failed to improve with standard treatments or were unwilling to use recommended medications because of their dangerous side effects. Therefore, clinicians should consider using activation immunotherapy, which enhances VDR expression and eliminates offending pathogens, in the clinical setting.

Review of Literature

1. Mangin M, Sinha R, Fincher K. Inflammation and vitamin D: the infection connection. Inflamm Res. Oct 2014;63(10):803-19.

2. Woolard MD, Frelinger JA. Outsmarting the host: bacteria modulating the immune response. Immunol Res. 2008;41(3):188-202.

3. Waterhouse JC, Marshall TG, Fenter B, Mangin M, Blaney G. High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor-implications of dysregulated vitamin D for diagnosis and treatment of chronic disease. In: Stolzt VD, ed. Vitamin D: New Research. New York, NY: Nova Science Publishers.

4. Hof H. Antibiotic Treatment of Infections with Intracellular Bacteria. In: Paradise LJ, Friedman H, Bendinelli M, eds. Opportunistic Intracellular Bacteria and Immunity. New York, NY: Kluwer Academic Press; 2002.

5. Hurley JC. Antibiotic-induced release of endotoxin. A therapeutic paradox. Drug Saf. Mar 1995;12(3):183-95.

"I am absolutely thrilled to see the work you and your group is doing. How invaluable and cutting edge. You will indeed change the world."  

C. Crosson

"Yes, it does feel like I am slowly getting better. It's pretty great!" Hexnut